Pacira BioSciences, Inc.
PCRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $2 | $2 | $3 |
| - Cash | $0 | $0 | $0 | $1 |
| + Debt | $1 | $1 | $1 | $1 |
| Enterprise Value | $1 | $2 | $2 | $3 |
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | 3.9% | 1.2% | 23.1% | – |
| Gross Profit | $1 | $0 | $0 | $0 |
| % Margin | 75.7% | 72.6% | 70.1% | 74.1% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 4.2% | 22.9% | 21.1% | 21% |
| Net Income | -$0 | $0 | $0 | $0 |
| % Margin | -14.2% | 6.2% | 2.4% | 7.8% |
| EPS Diluted | -2.15 | 0.89 | 0.34 | 0.92 |
| % Growth | -341.6% | 161.8% | -63% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |